Ask Warren

Hanall Biopharma

009420 · KOSPI · ₩009420 · 한올바이오파마

₩37,800▼ ₩700 (1.82%)End-of-day · Oct 29, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y +9.57%
Market cap
₩2T
Enterprise value
₩2T
P/E
—
P/B
12.2×
Dividend yield
0.0%
ROE
−15.4%
Net margin
−15.3%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−48.2% from the high

₩33,450Today: ₩37,050 – ₩39,100₩73,000

Returns

  • 1W−6.2%
  • 1M−12.6%
  • 3M−3.1%
  • 6M−20.3%
  • YTD−13.6%
  • 1Y+9.6%
Volume today
209,312
1.0× the 20-day average
Traded today
₩7.9B
Listed shares
52,240,638
EPS (12 months)
−₩477
Earnings yield −1.3%
SellBuy
AI research · InitiationHanall Biopharma: Thin Profits and Net Losses Alongside a High Price-to-Book MultipleThe data shows a company with steadily rising revenue but weak and inconsistent profitability, negative cash flow and a net loss in the latest period.Read the full report →

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

41Quiet
  • BuzzQuietBuzz 41 of 100 (50 is a normal day for this stock).
  • SentimentPositiveNews: Profit growth is positive, but lower sales offset some of the good news. Community: 0 bullish, 0 bearish posts this week.
  • MomentumWeak-12.9% over the last month; the price is below its 20-day average.
  • News impactSome8 news items and filings in two weeks; 0 rated high impact, 1 medium.

Signals describe activity, not recommendations. Not financial advice.

Leveraged ETF flows

Estimated leveraged-ETF rebalance on Oct 29: sell ₩66M at the close (0.7% of 20-day average trading value)

Sep 30Last 20 trading days (% of average trading value)Oct 29

On its 23 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 2.1% of trading value and pointed the same way 16 of 23 times.

  • -2× KODEX 200 Futures Inverse 2X −₩47M
  • 2× KODEX Leverage −₩5.7M
  • 2× TIGER 200IT Leverage −₩3.2M
  • -1× KODEX Inverse −₩2.8M
  • 2× TIGER Leverage −₩2.2M

Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.

Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.

Estimate based on ETF size and daily moves; actual trades may differ.

ETFs holding this

All ETFs →

Held by 32 funds.

Estimated from the funds' index or underlying stock.

Futures and options

All stock futures →

Futures (2026-11): 37,450

Basis −0.93% · implied rate −24.3%

Open interest 26,406 contracts

Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.

Hanall Biopharma stock overview

Hanall Biopharma (한올바이오파마, KRX: 009420) is listed on KOSPI, in the Biotech & Pharma sector. Hanall Biopharma is a South Korean pharmaceutical company, listed on the Korea Exchange since 1989, that researches, manufactures and sells synthetic and biopharmaceutical drugs in the domestic market. Its shares closed at ₩37,800 on Oct 29, 2026, down 1.82% on the day, giving it a market value of ₩2T.

Key facts

Market cap
₩2T
Sector
Biotech & Pharma
Latest price change
−1.82%
As of
Oct 29, 2026
Main business
Hanall Biopharma is a South Korean pharmaceutical company, listed on the Korea Exchange since 1989, that researches, manufactures and sells synthetic and biopharmaceutical drugs in the domestic market.

Quick answers about Hanall Biopharma

What does Hanall Biopharma do?
Hanall Biopharma is a South Korean pharmaceutical company, listed on the Korea Exchange since 1989, that researches, manufactures and sells synthetic and biopharmaceutical drugs in the domestic market. Its main products include the probiotic Biotop, the prostate cancer and central precocious puberty treatment Eligard, the non-absorbable antibiotic Normix, and hair loss treatments such as Hairgro. S.
What is the market cap of Hanall Biopharma?
The market capitalisation of Hanall Biopharma was ₩2T at the close on Oct 29, 2026.
Who are the largest shareholders of Hanall Biopharma?
According to the latest official filings, the largest reported holders are National Pension Service (10.63%, as of Oct 6, 2026); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (0.83%, as of Jul 31, 2026); iShares Core MSCI Emerging Markets ETF (0.70%, as of May 31, 2026).
When is the next earnings report from Hanall Biopharma?
Korean companies rarely announce results dates in advance. Based on when Hanall Biopharma filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Does the National Pension Service own Hanall Biopharma?
Yes. The National Pension Service held 10.56% of Hanall Biopharma shares as of Jul 1, 2026.

Company profile

Hanall Biopharma is a South Korean pharmaceutical company, listed on the Korea Exchange since 1989, that researches, manufactures and sells synthetic and biopharmaceutical drugs in the domestic market. Its main products include the probiotic Biotop, the prostate cancer and central precocious puberty treatment Eligard, the non-absorbable antibiotic Normix, and hair loss treatments such as Hairgro. The company focuses its R&D on biologic drugs for autoimmune, eye and neurological diseases, and its U.S. subsidiary HPI, Inc. handles overseas clinical trials and licensing.

Written by AI from the company's latest annual report.

Korean name
한올바이오파마
Sector
Biotech & Pharma
Themes
Biotech (new drugs)
CEO
박수진,박승국(공동대표이사)
Founded
Nov 1973
Listed
Dec 1989
Listed shares
52,240,638
Fiscal year ends
Month 12
Website
www.hanall.co.kr

Similar companies

Recent news

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: Hanall Biopharma / 한올바이오파마 / 009420 / KRX:009420

Source: KRX statistical information